Celecoxib

Name: Celecoxib
Brand: Selleck Chemicals
SKU: S1261
Rating: 5 (35 reviews)

For research use only.

Licensed by Pfizer Catalog No.S1261 Synonyms: SC 58635

35 publications

Molecular Weight(MW): 381.37

Celecoxib is a selective COX-2 inhibitor with IC50 of 40 nM in Sf9 cells.

Selleck's Celecoxib has been cited by 35 publications

Cell Death Differ, 2020, 20

PubMed: 32433558 ( click the link to review the publication )

J Clin Periodontol, 2020, 10.1111/jcpe.13283

PubMed: 32160330 ( click the link to review the publication )

Cancer Cell Int, 2020, 19;20:58

PubMed: 32099531 ( click the link to review the publication )

Cell Death Dis, 2020, 11(3):172

PubMed: 32139667 ( click the link to review the publication )

Osteoarthritis Cartilage, 2020, 28(4):502-515

PubMed: 32061965 ( click the link to review the publication )

Int Immunopharmacol, 2020, 81:106206

PubMed: 32018066 ( click the link to review the publication )

Cancer Lett, 2019, 440-441:116-125

PubMed: 30343113 ( click the link to review the publication )

Front Pharmacol, 2019, 10:836

PubMed: 31440159 ( click the link to review the publication )

J Cancer Res Clin Oncol, 2019, 145(6):1495-1507

PubMed: 31028540 ( click the link to review the publication )

Endocr J, 2019, 10.1507/endocrj.EJ19-0015

PubMed: 31105125 ( click the link to review the publication )

Viruses, 2019, 11(12)

PubMed: 31842327 ( click the link to review the publication )

Sci Transl Med, 2018, 10(433)

PubMed: 29563317 ( click the link to review the publication )

Oncol Lett, 2018, 16(1):317-325

PubMed: 29928417 ( click the link to review the publication )

Mucosal Immunol, 2018, 11(6):1663-1673

PubMed: 30082707 ( click the link to review the publication )

Nat Cell Biol, 2017, 19(10):1274-1285

PubMed: 28892080 ( click the link to review the publication )

Cancer Res, 2017, 77(3):790-801

PubMed: 27940576 ( click the link to review the publication )

Theranostics, 2017, 7(5):1389-1406

PubMed: 28435473 ( click the link to review the publication )

J Transl Med, 2017, 15(1):46

PubMed: 28231855 ( click the link to review the publication )

Biomed Pharmacother, 2017, 89:1235-1241

PubMed: 28320090 ( click the link to review the publication )

Oncol Rep, 2017, 38(5):2657-2666

PubMed: 29048666 ( click the link to review the publication )

J Pharm Biomed Anal, 2017, 145:586-592

PubMed: 28783595 ( click the link to review the publication )

Biochem Biophys Res Commun, 2017, 490(2):567-573

PubMed: 28624453 ( click the link to review the publication )

Oncol Lett, 2017, 14(5):5959-5965

PubMed: 29113232 ( click the link to review the publication )

Biochim Biophys Acta Gen Subj, 2017, 1861(2):264-275

PubMed: 27894925 ( click the link to review the publication )
J Pharm Sci, 2016, 105(3):1113-23

PubMed: 26886329 ( click the link to review the publication )

Oncotarget, 2016, 7(35):57077-57085

PubMed: 27494851 ( click the link to review the publication )

J Biol Chem, 2015, 290(52):30988-1002

PubMed: 26518876 ( click the link to review the publication )

J Cell Physiol, 2015, 230(5):1115-27

PubMed: ( click the link to review the publication )

Int J Pharm, 2015, 496(2):382-91

PubMed: 26468038 ( click the link to review the publication )

Drug Des Devel Ther, 2015, 9:5851-62

PubMed: 26586936 ( click the link to review the publication )

Biochem Bioph Res Co, 2015, 10.1016/j.bbrc.2015.03.008

PubMed: 25770423 ( click the link to review the publication )

Anticancer Res, 2015, 35(5):2699-708

PubMed: 25964548 ( click the link to review the publication )

Br J Pharmacol, 2014, 171(2):498-508

PubMed: 24372551 ( click the link to review the publication )

J Cell Physiol, 2014, 10.1002/jcp.24919

PubMed: 25546329 ( click the link to review the publication )

Blood, 2011, 118(22):5891-900

PubMed: 21865341 ( click the link to review the publication )

Purity & Quality Control

Choose Selective COX Inhibitors

Biological Activity

Description

Celecoxib is a selective COX-2 inhibitor with IC50 of 40 nM in Sf9 cells.

Targets

COX-2 ^[1]
(Sf9 cells)

40 nM

In vitro

Celecoxib shows low sensitivity against COX-1 with IC50 of 15 μM. ^[1] Celecoxib shows an anti-proliferative effect on nasopharyngeal carcinoma (NPC) cell lines including HNE1 and CNE1-LMP1 with IC50 of 32.86 μM and 61.31 μM, respectively. ^[2]

Cell Data

Cell Lines	Assay Type	Concentration	Incubation Time	Formulation	Activity Description	PMID
A549	NWLUOZdsTnWwY4Tpc44hSXO\|YYm=	MkTVNE4yNTNyIN88US=>	NYXhUphpPDhiaB?=		MljIbY5lfWOnczDJR2FONTFiZYjwdoV{e2mxbjDvckBjd3SqIIDyc5RmcW5iYX7kJI1TVkFibHX2[Yw>	M4f5e\|I3PTF\|MUey
H460	NXnHblRyTnWwY4Tpc44hSXO\|YYm=	NHP4ZWgxNjFvM{Cg{txO	M4HRXFQ5KGh?		NVvYOoFkcW6mdXPld{BKS0GPLUGg[ZhxemW\|c3nvckBwdiCkb4ToJJBzd3SnaX6gZY5lKG2UTlGgcIV3\Wx?	NGDCN\|MzPjVzM{G3Ni=>
HKESC-2	NFTWdlNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MYmyNOKh\|ryP	MV[0POKhcMLi		M4HuZ5Nq\26rZnnjZY51dHliaX7jdoVie2W\|IITo[UBKSzVywrD2ZYx2\XNib3[gc5hidGmybHH0bY7DqA>?	NHOzTlgzPjR5NE[5Ny=>
CaES-17	MYTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NILUO\|UzOMLizszN	MYe0POKhcMLi		NUThVmJ3e2mpbnnmbYNidnSueTDpcoNz\WG\|ZYOgeIhmKEmFNUFCpJZidHWnczDv[kBwgGGuaYDsZZRqdsLi	MViyOlQ4PDZ7Mx?=
HKESC-2	Mn:2RZBweHSxc3nzJGF{e2G7	M{fhd\|IxyqEQvF2=	NE[weZk1QMLiaNMg		NHu1TmNz\WS3Y3XzJI95[WyrcHzheIlvNWmwZIXj[YQh[XCxcITvd4l{	M4H5[\|I3PDd2Nkmz
CaES-17	MX3BdI9xfG:\|aYOgRZN{[Xl?	NYfhU4N2OjEEoN88US=>	NF3C[nU1QMLiaNMg		NYTucppremWmdXPld{BwgGGuaYDsZZRqdi2rbnT1Z4VlKGGyb4D0c5Nqew>?	M{i4fVI3PDd2Nkmz
A549	Mn7aS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MXi1MVE3OCEQvF2=	NHK5eJM1QMLiaNMg	NWrEZnhDTE2VTx?=	NYHVboM2UUN3ME2xOlMvPCEQvF2=	MXmyOlQ3PDZ2Mx?=
HCC827	M{X6d2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MVy1MVE3OCEQvF2=	Ml7BOFjDqGkEoB?=	MlrsSG1UVw>?	NXHTZnp7UUN3ME22PU4zKM7:TR?=	Ml7FNlY1PjR4NEO=
A549	MonMRZBweHSxc3nzJGF{e2G7	MkjMPFAhyrWP	M{T6bVQ5yqCqwrC=	MUfEUXNQ	NYTHfVdQcW6mdXPld{BieG:ydH;zbZM>	Mmr0NlY1PjR4NEO=
HCC827	MlLQRZBweHSxc3nzJGF{e2G7	MY[4NEDDvU1?	NIO1eZA1QMLiaNMg	NX61cZNZTE2VTx?=	NFLLbodqdmS3Y3XzJIFxd3C2b4Ppdy=>	Mn\XNlY1PjR4NEO=
SGC-7901/DDP	MU\GeY5kfGmxbjDBd5NigQ>?	NUX2WWp1OTEEoNM1US=>	NHTKfHAzPCCq		NHTDXY1qdmirYnn0d{BkgWOub3;4fYdmdmG\|ZT2yJIFv\CCSLXfsfYNweHKxdHXpckBmgHC{ZYPzbY9v	MnvYNlY1ODd4NUO=
SGC-7901	Mn\YS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?		NVTBUI1HOjUEoHlCpC=>		MXTJR\|UxRTFzNT6wPEDPxE1?	NV7nflk6OjZ2MEe2OVM>
SGC-7901/DDP	M4TWZWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7		MWqyOOKhcMLi		NInQSGFKSzVyPUO1MlQ2KM7:TR?=	MYWyOlQxPzZ3Mx?=
SGC-7901/DDP	M2rZVGFxd3C2b4Ppd{BCe3OjeR?=	NX;EeJc{OTEEoNM1US=>	M1;BOlI1KGh?		M1vQZolv\HWlZYOgZZBweHSxc3nzJINwdWKrbnXkJJdqfGhid3n0bEBkcXOybHH0bY4>	NIGxbJAzPjRyN{[1Ny=>
SGC-7901/DDP	MUHGeY5kfGmxbjDBd5NigQ>?	NWHtR5V7OTEEoNM1US=>	MWiyOEBp		MkfnbY5pcWKrdIOgeIhmKGW6cILld5Nqd25ib3[gVE1odHmlb4Dyc5RmcW5idHjyc5VocCCkbH;jb4lv\yCHUEKsJIFv\CCrbnHjeIl3[XSrbnegVGtCKGGwZDDDVmVDyqB?	MmXXNlY1ODd4NUO=
SGC-7901/DDP	M2TLTGZ2dmO2aX;uJGF{e2G7	NFfHSI4yOMLiwsXN	NVj4WJhrOjRiaB?=		NV\r[HV1[2G3c3XzJIEhdWG{a3XkJIRm[3KnYYPlJIlvKHSqZTDs[ZZmdCCxZjDCZ4wuOiCycn;0[Ylv	MnPFNlY1ODd4NUO=
H357	NYPvW5JoT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	M3;DZlcvPS9zMDFOwG0>	NVXyfpFIPDhiaB?=	MmrnSG1UVw>?	M3uxUYlvcGmkaYTzJINmdGxiZ4Lve5RpyqClb33ibY5m\CC5aYToJHNi[nW2b3PsZZg>	M2nHRlI3ODB7OEe0
TAF	MYDGeY5kfGmxbjDBd5NigQ>?	M3SzPFExyqEEtV2=	Mn\uO{Bl		MmfhZYZn\WO2czDURWZ{KGGmaHXzbZZmKHC{b4DldpRq\XN?	MX[yOVk5PzF{Nx?=
TAF	NFfLbmZHfW6ldHnvckBCe3OjeR?=	M1jyXFExyqEEtV2=	NFLoWlc{OC1zMkCgcYlv		MmrUdI9wemy7IHHm[oVkfHNiZFHreEBxcG:\|cHjvdplt[XSrb36gZ49ve2WzdXXueEB1dyCHR1[gd4lodmGuaX7n	NF7rb2czPTl6N{GyOy=>
TAF	M3z6NWZ2dmO2aX;uJGF{e2G7	MV:xNOKhyrWP	MoPLOFghcA>?		MYDpcoNz\WG\|ZYOgSWdHWiCvUl7BJIFv\CCycn;0[YlvKGW6cILld5Nqd25?	NV7YZZpQOjV7OEexNlc>
PANC-1	M2L6eGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NFXC[\|YzOC94MD:xNFAh\|ryP	MUCyOE81QC95MjDo		NIXmfJVqdmirYnn0d{Bk\WyuIHfyc5d1cCCrbjDic5RpKHSrbXWgZY5lKGSxc3Wg[IVx\W6mZX70JI1idm6nch?=	NFPLUHEzPTl5M{C2Ni=>
PANC-1	NV3STIw1TnWwY4Tpc44hSXO\|YYm=	MXWyNE83OC9zMECg{txO	NEP4VGEzPCCq		MXfheJRmdnWjdIOgZ4VtdCCrbo\hd4lwdiCjbnSgcYloemG2aX;uJIlvKGFiY3;uZ4VvfHKjdHnvck1l\XCnbnTlcpQhdWGwbnXyxsA>	MofWNlU6PzNyNkK=
HeLa	MoDKS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NET3ZXYzOMLizszNxsA>	M{Lpb\|I1yqCq		M1nCZoVvcGGwY3XzJJJi\GmjdHnvck1qdmS3Y3XkJIlvcGmkaYTpc44hd2ZiY3XscEBxem:uaX\ldoF1cW:w	MVOyOVc4ODR{Mx?=
SACC-83	NYj5[Zc{T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	M1zRelIxyqEQvF5CpC=>	M2rE[FI1yqCq		MVnlcohidmOnczDyZYRq[XSrb36tbY5lfWOnZDDpcohq[mm2aX;uJI9nKGOnbHygdJJwdGmoZYLheIlwdg>?	MX:yOVc4ODR{Mx?=
HeLa	M2fzV2Fxd3C2b4Ppd{BCe3OjeR?=	NGPQUVYzOMLizszNxsA>	MmHqNlTDqGh?		MYjlcohidmOnczDyZYRq[XSrb36tbY5lfWOnZDDpcohq[mm2aX;uJI9nKGOnbHygZZBweHSxc3nz	M3\aS\|I2PzdyNEKz
SACC-83	NGq2NZRCeG:ydH;zbZMhSXO\|YYm=	MnLONlDDqM7:TdMg	Mnj5NlTDqGh?		NUjTdFBi\W6qYX7j[ZMhemGmaXH0bY9vNWmwZIXj[YQhcW6qaXLpeIlwdiCxZjDj[YxtKGGyb4D0c5Nqew>?	MmLlNlU4PzB2MkO=
HeLa	MkDHSpVv[3Srb36gRZN{[Xl?	M33rUlIxNzRyL{iwJO69VQ>?	MnLDNlTDqGh?		Mly0eZBz\We3bHH0d{BRXEWQIIDhdpRq[WyueTDifUBqdmirYnn0bY5oKFOyMTygZY5lKGGldHn2ZZRmeyCSVFXOJIFv\CCrbnHjeIl3[XSnczDBT3Q>	M{fIb\|I2PzdyNEKz
SACC-83	MoLpSpVv[3Srb36gRZN{[Xl?	MYqyNE81OC96MDFOwG0>	MVKyOOKhcA>?		MYj1dJJm\3WuYYTzJHBVTU5icHHyeIlidGy7IHL5JIlvcGmkaYTpcochW3BzLDDhcoQh[WO2aY\heIV{KFCWRV6gZY5lKGmwYXP0bZZifGW\|IFHLWC=>	M4jPNVI2PzdyNEKz
HLCZ01	MnTDS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NGn1cnkx6oDVNkFCpOK2VQ>?	MX60PEBp	M3rBWmROW09?	M2riO4lvcGmkaYTzJINmdGxiZ4Lve5RpKGmwIHGg[I9{\SCmZYDlcoRmdnRibXHucoVz	NX;mTFkyOjV5MkS4PVk>
HLCZ01	NH\JV2pHfW6ldHnvckBCe3OjeR?=	NHfyW4k1OMLizszN	M{TKc\|I1KGh?	NHvsPJRFVVOR	MWrpcoNz\WG\|ZYOgZYNkfW23bHH0bY9vKG:oIFewM2cyNXCqYYPlJINmdGy\|IHPvcYJqdmWmIIfpeIghUU[QLd8x	M{C0ZVI2PzJ2OEm5
HLCZ01	NHztV2ZCeG:ydH;zbZMhSXO\|YYm=	NHjmXWI1OMLizszN	MVGyOEBp	MmPBSG1UVw>?	M3TiT4VvcGGwY3XzJIFxd3C2b4Ppd{Bkd22kaX7l[EB4cXSqIFnGUk3PuQ>?	MkDrNlU4OjR6OUm=
HLCZ01	M{HsTmZ2dmO2aX;uJGF{e2G7	M{nlTVQxyqEQvF2=	MkDWNlQhcA>?	NY[wdpI1TE2VTx?=	NGnhUGtqdmO{ZXHz[ZMhXFKDSVyg[ZhxemW\|c3nvckBkd22kaX7l[EB4cXSqIFnueIVz\mW{b36t{tE>	M3vCTVI2PzJ2OEm5
MGC803	NVXZR3g{T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MlHMNE03OCEQvF2=	MmTwO\|IhcA>?		MnrZTWM2OD12Nz6yOgKBkcLz4pEJOk41OyEQvF2=	MkfWNlU4ODF\|N{i=
SGC7901	Ml;VS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	Mmn1NE03OCEQvF2=	NY[x[lZtPzJiaB?=		NUPWU29FUUN3ME20N{42O+LCidMx5qCKPS5zMjFOwG0>	MnvGNlU4ODF\|N{i=
MGC803	NUPoXnhMTnWwY4Tpc44hSXO\|YYm=	NH;XWWQ1OMLizszN	Ml7sPE8yPi9{NDDo		M{PlZ5VxemWpdXzheJMhS2KuLXKg[ZhxemW\|c3nvci=>	NYXCOGNPOjV5MEGzO\|g>
SGC7901	MoXTSpVv[3Srb36gRZN{[Xl?	NHnucGc1OMLizszN	MYK4M\|E3NzJ2IHi=		M1L2N5VxemWpdXzheJMhS2KuLXKg[ZhxemW\|c3nvci=>	NHTWZWQzPTdyMUO3PC=>
MCF-7	MYDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	M3vxcFEwOTBizszN	Ml3jO\|IhcA>?	NYnBS3R{TE2VTx?=	MYTlcohidmOnczDjZYxkcXS{aX;sMYlv\HWlZXSgZ4VtdCCpcn;3eIghcW6qaXLpeIlwdg>?	MWKyOVY3PzVzMB?=
MDA-MB-231	MULHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NHTiU5MyNzFyIN88US=>	NGrHVoE4OiCq	NGPYcmpFVVOR	MmDq[Y5p[W6lZYOgZ4Ft[2m2cnnvcE1qdmS3Y3XkJINmdGxiZ4Lve5RpKGmwaHnibZRqd25?	NYLBPGVKOjV4Nke1NVA>
MDA-MB-231	MVTGeY5kfGmxbjDBd5NigQ>?	MUWwMVQxKML3TR?=	NUHSb\|lzPC1{NDDo		NIDLcZdqdmO{ZXHz[ZMhS0:[LUKgdJJwfGWrbjDlfJBz\XO\|aX;uJIlvKGKxdHigeIlu\SCjbnSg[I9{\SCmZYDlcoRmdnRibXHucoVz	MYKyOVU5PzN{OR?=
MCF-7	NEHrdnBHfW6ldHnvckBCe3OjeR?=	NF\rO4gxNTRyINM1US=>	MoLyOE0zPCCq		MlHl[Y5p[W6lZYOgeIhmKGWoZnXjeJMhd2ZiVGDBJI9vKEGEQ1eyJIV5eHKnc4Ppc47DqA>?	MUOyOVU5PzN{OR?=
MCF7-MX	NHH6WHpHfW6ldHnvckBCe3OjeR?=	NYHJSGhIOC12MDFCuW0>	Mn;TOE0zPCCq		M3;CRYVvcGGwY3XzJJRp\SCnZn\lZ5R{KG:oIGTQRUBwdiCDQlPHNkBmgHC{ZYPzbY9vyqB?	M3vKSlI2PTh5M{K5
MDA-MB-231	NWPORml2TnWwY4Tpc44hSXO\|YYm=	MnzhNE01OCEEtV2=	NILURmo1NTJ2IHi=		M2XzVZN1cW23bHH0[ZMhfGinIHX4dJJme3Orb36gc4YhSUKFR{KgeZAhfG9iND6yO{B1cW2nczD0c{Bkd262cn;sJIxmfmWuIHL5JFEzKGkEoB?=	NH;wbWIzPTV6N{OyPS=>
A2780	M375V2Z2dmO2aX;uJGF{e2G7	NYHIRoR6PS9zMD:xOUDPxE1?	MojvOFghcA>?		Mkjy[IVkemWjc3XzJGNwgC1{IHX4dJJme3Orb36gbY4h[SCmb4PlMYRmeGWwZHXueEBu[W6wZYK=	MnrxNlU1OjR6OUi=
SKOV3	NHvHXXhHfW6ldHnvckBCe3OjeR?=	NGS1VHc2NzFyL{G1JO69VQ>?	NVTSUHRJPDhiaB?=		M{\5eIRm[3KnYYPld{BEd3hvMjDlfJBz\XO\|aX;uJIlvKGFiZH;z[U1l\XCnbnTlcpQhdWGwbnXy	MVSyOVQzPDh7OB?=
A2780	NVnzdnF1TnWwY4Tpc44hSXO\|YYm=	MXK1M\|ExNzF3IN88US=>	NGTScok1QCCq		MkPY[YxmfmG2ZYOgeIhmKGW6cILld5Nqd25ib3[gSU1k[WSqZYLpckBidmRia3XyZZRqdg>?	MoKwNlU1OjR6OUi=
SKOV3	MnrPSpVv[3Srb36gRZN{[Xl?	Mn35OU8yOC9zNTFOwG0>	MlzjOFghcA>?		MWDlcIV3[XSnczD0bIUh\XiycnXzd4lwdiCxZjDFMYNi\GincnnuJIFv\CCtZYLheIlv	NFXSVnAzPTR{NEi5PC=>
A2780	M1\4UGZ2dmO2aX;uJGF{e2G7	NWDNWIVoPS9zMD:xOUDPxE1?	NHLZdnc1QCCq		NUjnNZVo\GWlcnXhd4V{KHSqZTDlfJBz\XO\|aX;uJI9nKE5vY3HkbIVzcW5iYX7kJHZqdWWwdHnu	NYDzWG9LOjV2MkS4PVg>
SKOV3	M2jCNGZ2dmO2aX;uJGF{e2G7	MmXBOU8yOC9zNTFOwG0>	MYi0PEBp		NXfsfJFX\GWlcnXhd4V{KHSqZTDlfJBz\XO\|aX;uJI9nKE5vY3HkbIVzcW5iYX7kJHZqdWWwdHnu	NETwRWYzPTR{NEi5PC=>
A2780	MlywSpVv[3Srb36gRZN{[Xl?	MkDhOU8yOC9zNTFOwG0>	Mof5NUBp		M{PMOIlv[3KnYYPld{B1cGViZYjwdoV{e2mxbjDv[kBxNUGNVDDhcoQheC2HUlugbY4h[SCmb4PlMYRmeGWwZHXueEBu[W6wZYK=	MUKyOVQzPDh7OB?=
SKOV3	NXXjVJBZTnWwY4Tpc44hSXO\|YYm=	NFS4VFE2NzFyL{G1JO69VQ>?	NG\oSngyKGh?		MVPpcoNz\WG\|ZYOgeIhmKGW6cILld5Nqd25ib3[gdE1CU1RiYX7kJJAuTVKNIHnuJIEh\G:\|ZT3k[ZBmdmSnboSgcYFvdmW{	MYOyOVQzPDh7OB?=
HCT-15	NELjbW1HfW6ldHnvckBCe3OjeR?=	MlS3NVAuPTBizszN	M4Hh[\|YuOzZiaB?=		MnywbY5lfWOnczD0bIUh\XiycnXzd4lwdiCxZjDDU3guOiCrbjDic5RpKGSxc3WgZY5lKHSrbXWg[IVx\W6mZX70JI1idm6nch?=	NELxcVIzPTJzOECyPC=>
HT-29	NXvue2tWTnWwY4Tpc44hSXO\|YYm=	NXvINGdkOTBvNUCg{txO	NFq2UY03NTN4IHi=		Mn7ubY5lfWOnczD0bIUh\XiycnXzd4lwdiCxZjDDU3guOiCrbjDic5RpKGSxc3WgZY5lKHSrbXWg[IVx\W6mZX70JI1idm6nch?=	MXOyOVIyQDB{OB?=
HSC3	MYrD[YxtKF[rYXLpcIl1gSCDc4PhfS=>	NHf5bGIx6oDVNECg{txO	MmPuOFghcA>?		NUm3T4Z2UUN3ME2yOU42yrFzLke4NEDPxE1?	MoLvNlUyQTh5OEm=
HSC3	M2DZZmFxd3C2b4Ppd{BCe3OjeR?=	M3r6NVI2KM7:TR?=	M{SyVlQ5KGh?		M1;ld4lv\HWlZYOgZZBweHSxc3nz	M4Lwd\|I2OTl6N{i5
HSC3	MULGeY5kfGmxbjDBd5NigQ>?	MlnGNlUh\|ryP	M2LqcVQ5KGh?		MYnlfIhq[mm2czDzbYdvcW[rY3HueIx6KHKnZIXj[YQhdWmpcnH0bY9vKGOxbXLpcoVlKHerdHigR2VV	NX64XYdDOjVzOUi3PFk>
HSC3	NGr1[oxHfW6ldHnvckBCe3OjeR?=	MkOyNlUh\|ryP	NVu4epd4PDhiaB?=		NXq1NYM3cW6qaXLpeJMhUFOFMzDj[YxtKGmwdnHzbY9vKGOxbXLpcoVlKHerdHigR2VV	NIXWd5MzPTF7OEe4PS=>
HSC3	NYryUVRkTnWwY4Tpc44hSXO\|YYm=	MX[yOUDPxE1?	NFX0O204OiCq		NELJRpdl\WO{ZXHz[ZMhVU2SLUKgZY5lKE2PUD25JJBzd3SnaX7zxsA>	MkTmNlUyQTh5OEm=
201T	M1HUV2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7		NF7oWHU4OiCq	NUDwXHhKTE2VTx?=	M1qzPWlEPTB;NEiuOkDDvU1?	M{LSS\|I2ODV5OUSx
273T	MYDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?		NXXLW49YPzJiaB?=	MnLxSG1UVw>?	MUDJR\|UxRThyLkWgxtVO	M1;HTVI2ODV5OUSx
Hep-2	NXzyXZRLT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MYGzNE82OC9zMECg{txO	MV2xNk8zPC9\|Nj:0PEBp	NUnHSlJJTE2VTx?=	NULGPXhEcW6qaXLpeJMh[2WubDDndo94fGhiaX6gZo91cCC2aX3lJIFv\CCmb4PlJIRmeGWwZHXueEBu[W6wZYK=	NHTSU3EzPDl7OEW2OC=>
Hep-2	NWjMV484SXCxcITvd4l{KEG\|c3H5	MVO1NEDPxE1?	NGLVd\|gxNTR6IHi=	NHvjOYNFVVOR	Mo\sbY5lfWOnczDhdI9xfG:\|aYOgbY4h[SC2aX3lJIRmeGWwZHXueEBu[W6wZYK=	NV30eoRVOjR7OUi1OlQ>
Hep-2	M3rJOmZ2dmO2aX;uJGF{e2G7	NH\JVIU2OCEQvF2=	NHPYUm4xNTR6IHi=	MoPZSG1UVw>?	MmridoVlfWOnczD0bIUhfGWub33ldoF{\SCjY4Tpeol1gSCpcnHkeYFtdHl?	MnjrNlQ6QTh3NkS=
Hep-2	M4fIR2Z2dmO2aX;uJGF{e2G7	MWO1NEDPxE1?	M{n0WlAuPDhiaB?=	NIS5bJpFVVOR	M{XCPYRm[3KnYYPld{B1cGVibWLORUBmgHC{ZYPzbY9vKG:oIHjUSXJV	MkTzNlQ6QTh3NkS=
SGC-7901	NFK0bWhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	M3i4WVExNzVyL{GwNEDPxE1?	Moj4NlQwPDhxN{KgbC=>	NVizVHB7TE2VTx?=	NWjteVNXcW6qaXLpeJMh[2WubDDndo94fGhiaX6gZo91cCC2aX3lJIFv\CCmb4PlJIRmeGWwZHXueEBu[W6wZYK=	Mn\iNlQ6QTJ7NUi=
MKN-45	NY\rXnQ{T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NUfHSoJ7OTBxNUCvNVAxKM7:TR?=	M{jZcFI1NzR6L{eyJIg>	NF;zcFZFVVOR	MkDYbY5pcWKrdIOgZ4VtdCCpcn;3eIghcW5iYn;0bEB1cW2nIHHu[EBld3OnIHTldIVv\GWwdDDtZY5v\XJ?	NG\EU2wzPDl7Mkm1PC=>
SGC-7901	NEnuN2RHfW6ldHnvckBCe3OjeR?=	M3TtU\|ExNzVyL{GwNEDPxE1?	MnvYOFghcA>?	NFq1W5hFVVOR	Mnjw[I94dnKnZ4XsZZRmeyC2aHWgcXJPSSCneIDy[ZN{cW:wIHzleoVteyCxZjDDU3guOiCjbnSgVGNPSSCrbjDhJIRwe2ViZHXw[Y5l\W62IH3hco5meg>?	NU\SRXdlOjR7OUK5OVg>
MKN-45	MnH1SpVv[3Srb36gRZN{[Xl?	NX\DS\|RQOTBxNUCvNVAxKM7:TR?=	NIrKWGM1QCCq	MWHEUXNQ	Mlzx[I94dnKnZ4XsZZRmeyC2aHWgcXJPSSCneIDy[ZN{cW:wIHzleoVteyCxZjDDU3guOiCjbnSgVGNPSSCrbjDhJIRwe2ViZHXw[Y5l\W62IH3hco5meg>?	M1LUR\|I1QTl{OUW4
C666-1	NF:1PGVEgXSxdH;4bYNqfHliQYPzZZk>	M3y1b\|IxNThyIN88US=>	M2rTR\|I1KGh?		NX[wTG1k\GWlcnXhd4V{KGOxbH;ufUBnd3KvYYTpc44hcW5iYTDkc5NmNWSncHXu[IVvfCCvYX7u[ZLDqA>?	MXOyOFg2PDh\|OB?=
CNE-1	MVLDfZRwfG:6aXPpeJkhSXO\|YYm=	NWLXV4p5OjBvOECg{txO	NWrTUHFzOjRiaB?=		Mmqy[IVkemWjc3XzJINwdG:weTDmc5Ju[XSrb36gbY4h[SCmb4PlMYRmeGWwZHXueEBu[W6wZYNCpC=>	NFLnRpozPDh3NEizPC=>
CNE-2	MULDfZRwfG:6aXPpeJkhSXO\|YYm=	NXPmeZZ2OjBvOECg{txO	MnnwNlQhcA>?		MUTk[YNz\WG\|ZYOgZ49td267IH\vdo1ifGmxbjDpckBiKGSxc3Wt[IVx\W6mZX70JI1idm6nctMg	NUDIblR3OjR6NUS4N\|g>
C666-1	NUTlSol3S3m2b4TvfIlkcXS7IFHzd4F6	NX;KVIdjPjBizszN	M1rre\|ch\A>?		NYOxbIZ1\W6qYX7j[ZMhemGmaXH0bY9vKGO7dH;0c5hq[2m2eTD0bJJwfWeqIFPPXE0zNWSncHXu[IVvfCCvYX7u[ZI>	NYq0dmhEOjR6NUS4N\|g>
CNE-1	NF61V\|lEgXSxdH;4bYNqfHliQYPzZZk>	NED6TZg3OCEQvF2=	MUO3JIQ>		M{TyfoVvcGGwY3XzJJJi\GmjdHnvckBkgXSxdH;4bYNqfHlidHjyc5VocCCFT2itNk1l\XCnbnTlcpQhdWGwbnXy	MlrzNlQ5PTR6M{i=
SNU-1041	M{fQeGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NHTOfo8xNTRyIN88US=>	MlL3OFghcA>?		NFLJRo1qdmirYnn0d{Bk\WyuII\pZYJqdGm2eTDpckBiKGSxc3Wg[IVx\W6mZX70JI1idm6nch?=	NIjre5czPDZ7MkewNy=>
SNU-1041	MYnGeY5kfGmxbjDBd5NigQ>?	MVWyNE8{OCEQvF2=	NFPZTpU1KGh?		NGX5XXpqdmS3Y3XzJIV5eHKnc4Ppc44hd2cEoFPIU3AtKEeUUEe4xsBidmUEoGjCVFHDqGG2IITo[UBTVkFibHX2[YzDqA>?	NUXJWJl2OjR4OUK3NFM>
SNU-1041	M2HObGZ2dmO2aX;uJGF{e2G7	MXOwMVQxKM7:TR?=	NXPJVFZoPCCq		M2fhZpVxNXKnZ4XsZZRmeyCFSF;QxsBi\nSncjD0doVifG2nboSge4l1cCCqaXfoJINwdmOnboTyZZRqd26\|	NX3WT2prOjR4OUK3NFM>
SGC-7901	MlvaS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	M3fQRVUxNTF{NTFOwG0>	M2HZTFI1NzR6L{eyJIg>		M{LkV4lvcGmkaYTzJINmdGxiZ4Lve5RpKGmwIHLveIghfGmvZTDhcoQh\G:\|ZTDk[ZBmdmSnboSgcYFvdmW{	NILvfZIzPDZ5NkO5OC=>
SGC-7901	Moi3RZBweHSxc3nzJGF{e2G7	MVSxNFAh\|ryP	M{LqTlczKGh?		M4XSUIlv\HWlZYOgZZBweHSxc3nz	MYSyOFY4PjN7NB?=
SGC-7901	MkD4SpVv[3Srb36gRZN{[Xl?	M4fC[Vc2NzFyMD:xNlUh\|ryP	NGLnWHAzPC92OD:3NkBp		NGjzZ5ZqdmO{ZXHz[ZMh[2G\|cHHz[U05KGGwZDCtPUBuWk6DIHX4dJJme3Orb36gbY4h[m:2aDD0bY1mKGGwZDDkc5NmKG2jbn7ldi=>	NXjn[ZdCOjR4N{[zPVQ>
LMeC	NXzkXJAxTnWwY4Tpc44hSXO\|YYm=	M1vLfVIxNzVyIN88US=>	MVy0PEBp		NYe2Z3ZY\GWlcnXhd4V{KHSqZTDlfJBz\XO\|aX;uJI9nKEORWD2yJJBzd3SnaX6=	MV[yOFY2Pjd2Nh?=
CMeC-1	MknLR4VtdCCYaXHibYxqfHliQYPzZZk>	NXfwcI41OjBxNUCg{txO	NIrMRW81QCCq		NXjSe5JJcW6qaXLpeJMh[2WubDD2bYFjcWyrdImgbY4h[SCmb4PlJIRmeGWwZHXueEBu[W6wZYK=	NXnmcmZmOjR4NU[3OFY>
LMeC	NHzL[pRE\WyuIG\pZYJqdGm2eTDBd5NigQ>?	NFvyOnQzOC93MDFOwG0>	NI\UUnk1QCCq		MWXpcohq[mm2czDj[YxtKH[rYXLpcIl1gSCrbjDhJIRwe2ViZHXw[Y5l\W62IH3hco5meg>?	M{P1ZlI1PjV4N{S2
CMeC-1	M{PDUGZ2dmO2aX;uJGF{e2G7	NVzocGZROjBxNUCg{txO	NWHpcHNwPDhiaB?=		Mn;LbY5lfWOnczDHNU1UKGG{cnXzeC=>	M1jOR\|I1PjV4N{S2
LMeC	MX7GeY5kfGmxbjDBd5NigQ>?	NGHnZZczOC93MDFOwG0>	M362fVQ5KGh?		MUDpcoR2[2W\|IFexMXMh[XK{ZYP0	MnLlNlQ3PTZ5NE[=
CMeC-1	M4nYTmZ2dmO2aX;uJGF{e2G7	MYeyNE82OCEQvF2=	M4HWV\|Q5KGh?		MUPk[YNz\WG\|ZYOgeIhmKGyndnXsd{Bw\iCleXPsbY4hTDFiaX6gZUBld3OnLXTldIVv\GWwdDDtZY5v\XJ?	MUKyOFY2Pjd2Nh?=
LMeC	MXLGeY5kfGmxbjDBd5NigQ>?	NWDHOJVZOjBxNUCg{txO	NYPYOWpYPDhiaB?=		NVToTJpM\GWlcnXhd4V{KHSqZTDs[ZZmdHNib3[gZ5lkdGmwIFSxJIlvKGFiZH;z[U1l\XCnbnTlcpQhdWGwbnXy	NV;CTGo4OjR4NU[3OFY>
CMeC-1	M4HVO2Z2dmO2aX;uJGF{e2G7	MWqyNE82OCEQvF2=	M2K4UVQ5KGh?		MnyxbY5lfWOnczDjZZNx[XOnLUOgZYN1cX[jdHnvci=>	NYHhW2F{OjR4NU[3OFY>
LMeC	MkDRSpVv[3Srb36gRZN{[Xl?	NXXJeng{OjBxNUCg{txO	MlPNOFghcA>?		M{fpfIlv\HWlZYOgZ4F{eGG\|ZT2zJIFkfGm4YYTpc44>	M3j3SVI1PjV4N{S2
OVCAR-3	MnOyR4VtdCCYaXHibYxqfHliQYPzZZk>	MkHlNVAhyrWP	MYKxJIg>		NH7uN4VmdmijbnPld{Bx[WOuaYThfIVtNWmwZIXj[YQhd3[jcnnhckBk[W6lZYKgZ4VtdCCmZXH0bOKh	M2f5cVI1PTJyMkK3
OVCAR-3	NH;ldopCeG:ydH;zbZMhSXO\|YYm=	M32xb\|ExKML3TR?=	MYKxJIg>		MXvwdo9ud3SnczDwZYNtcXSjeHXsMYlv\HWlZXSgZZBweHSxc3nzxsA>	MYeyOFUzODJ{Nx?=
OVCAR-3	MXvGeY5kfGmxbjDBd5NigQ>?	NEXnTYgyOCEEtV2=	NGO4fYkyKGh?		M{PzeYVvcGGwY3XzJJBi[2yrdHH4[YwucW6mdXPl[EBi[3SrdnH0bY9vKG:oIHPhd5Bie2VvOdMg	NX3VV2M2OjR3MkCyNlc>
OVCAR-3	M4e1dWZ2dmO2aX;uJGF{e2G7	NE\wPZUyOCEEtV2=	MWSxJIg>		MlPO[I94di2{ZXf1cIF1\XNiTl[t{tpDKGGldHn2ZZRqd25iaX7keYNm\CCkeTDwZYNtcXSjeHXs	MknaNlQ2OjB{Mke=
OVCAR-3	NHficYxHfW6ldHnvckBCe3OjeR?=	MmLiNVAhyrWP	MnfjNUBp		MYjpcohq[mm2czDwZYNtcXSjeHXsMYlv\HWlZXSgRYt1KHCqb4PwbI9zgWyjdHnvci=>	MYiyOFUzODJ{Nx?=
CF33	NHvGV41HfW6ldHnvckBCe3OjeR?=	MnX6NVAxKM7:TR?=	NHzlT3EzPCCq		MonVbY5lfWOnczDkc5dvemWpdXzheIlwdiCxZjDDU3guOiCycn;0[YlvKGW6cILld5Nqd25?	M1X6PFI1PTB\|N{iy
CF33	NFPhO2JIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NEG4O2wyOC1zMECg{txO	MmDENE01KGR?		M2THb4lvcGmkaYTzJINmdGxicILvcIln\XKjdHnvckBqdiCjIHTvd4Uu\GWyZX7k[Y51KG2jbn7ldi=>	MmjENlQ2ODN5OEK=
CF33	M3HybmZ2dmO2aX;uJGF{e2G7	MUexNE0yODBizszN	MnPwOE0zPCCq		M1jSUYRm[3KnYYPld{Bk\WyuczDpckB1cGViUzDwbIF{\SCjbnSgbY5kemWjc3XzJINmdGy\|IHnuJGcxN0dzIHHydoV{fA>?	M1fpcVI1PTB\|N{iy
LNCaP	NX7scHR5T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	M3vzdVIwPS9zMDFOwG0>	MUm5OkBp		NXG2U4VScW6qaXLpeJMh[2WubDDndo94fGhic3nncolncWOjboTsfUBkd22kaX7l[EB4cXSqIHH0c5J3[XO2YYTpci=>	M3GzZVI1Ojl4OUe4
LNCaP	M13abWFxd3C2b4Ppd{BCe3OjeR?=	M1PGbVIwPS9zMDFOwG0>	M1;0blk3KGh?		MXXpcoR2[2W\|IHHwc5B1d3OrczDjc41jcW6nZDD3bZRpKGG2b4L2ZZN1[XSrbh?=	NHTac2czPDJ7Nkm3PC=>
PC-3	NWT1OlRQT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MlLJNE02OCEQvF2=	MlfJOFjjiImq		M3O1UYlvcGmkaYTzJINmdGxiZ4Lve5RpKGmwIHGg[I9{\SCmZYDlcoRmdnRibXHucoVz	NXnFSYdMOjRzMke4PFI>
PC-3	MkTQR4VtdCCYaXHibYxqfHliQYPzZZk>	NWe3RWRGOC1zMECg{txO	M1r4TFczKGh?		M2TwXIRm[3KnYYPld{Bk\WyuII\pZYJqdGm2eTDpckBiKGSxc3Wg[IVx\W6mZX70JI1idm6nch?=	MmPhNlQyOjd6OEK=

... Click to View More Cell Line Experimental Data

Assay

Methods	Test Index	PMID
Western blot	Fibronectin / Vimentin / N-cadherin / E-cadherin ; PubMed: 28978083 Oncotarget (A) Celecoxib treatment reduces the mesenchymal phenotype in SUM149 cells. COX-2; PubMed: 29515134 Sci Rep L02 cells exposed to PA (200 μM) with different concentrations of celecoxib (Cel, 5-40 μM) for 24 h. Celecoxib decreased protein expression of COX-2 compared with control as indicated by western blot. pAKT / AKT / PPARγ / PTEN ; PubMed: 24721996 Oncotarget Immunoblots from N1-S1 cells treated with different dose celecoxib for 48 h.	28978083 29515134 24721996
Immunofluorescence	PPARγ / PTEN ; PubMed: 24721996 Oncotarget Immunofluorescence analysis in N1-S1 cells treated with 10 μM celecoxib for 48 h.	24721996
Growth inhibition assay	Cell viability; PubMed: 28521485 Oncol Lett Celecoxib caused the concentration-dependent inhibition of (A) GBC-SD and (B) NOZ cell growth.	28521485

In vivo

Celecoxib exhibits a potent, oral anti-inflammatory activity. Celecoxib reduces acute inflammation in the carrageenan edema assay and chronic inflammation in the adjuvant arthritis model with ED50 of 7.1 mg/kg and 0.37 mg/kg/day, respectively. In addition, Celecoxib also exhibits analgesic activity in the Hargreaves hyperalgesia model with ED50 of 34.5 mg/kg. Besides, Celecoxib produces no acute GI toxicity in rats at doses up to 200 mg/kg and no chronic GI toxicity in rats at doses up to 600 mg/kg/day over 10 days. ^[1] In a C3Hf/KamLaw female mouse model, Celecoxib increases median survival time of 105 days (range, 79-145 days) after 13.5 Gy local thoracic irradiation (LTI) alone to 142 days (range, 94-155 days). ^[3]

Protocol

Kinase Assay:^[1]	- Collapse COX enzyme assay in vitro: Expression of COX protein in insect cells is determined by assessing PG-synthetic capability in homogenates from cells incubated for 3 days with COX-1 or COX-2 baculovirus. Cells expressing COX-1 or COX-2 are homogenized and incubated with arachidonic acid (10 μM). COX activity is determined by monitoring PG production. No COX activity is detected in mock-infected Sf9 cells. Celecoxib are preincubated with crude 1% CHAPS homogenates (2-10 μg of protein) for 10 minutes before addition of arachidonic acid. PGE2 formed is detected by ELISA after 10 minute incubation.
Cell Research:^[2]	- Collapse Cell lines: HNE1 and CNE1-LMP1 Concentrations: 0-75 μM Incubation Time: 48 hours Method: The antiproliferative effect of Celecoxib on NPC cells is assessed using an MTT assay. Cells are seeded into 96-well plates and allowed to attach for 24 hours. The cells are then treated with increasing concentrations of Celecoxib (0 to 75 μM) dissolved in DMSO (final concentration ≤0.1%) and incubated for up to 48 hours. After the incubation, 20 μL of MTT dye (5 mg/mL) are added to each well and cells are incubated at 37 °C for 4 hours. After removing the supernatants, the crystals are dissolved in DMSO and the absorbance is measured at 490 nm. The half-maximal inhibitory concentration (IC50) values and the 95% confidence intervals are calculated using probit regression using SPSS 15.0 software. The experiment is performed in triplicate and repeated at least three times. (Only for Reference)
Animal Research:^[1]	- Collapse Animal Models: A 0.1 mL aliquot of a 1% solution of carrageenan in 0.9% sterile saline or 1 mg of Mycobacterium butyricum in 50 μL of mineral oil is administered to the right hind foot pad of male Sprague−Dawley rats. Dosages: ≤200 mg/kg Administration: Administered via p.o. (Only for Reference)

References

Solubility (25°C)

In vitro	DMSO	76 mg/mL (199.28 mM)
	Ethanol	33 mg/mL (86.53 mM)
	Water	Insoluble
In vivo	Add solvents to the product individually and in order(Data is from Selleck tests instead of citations): 2% DMSO+30% PEG 300+5% Tween 80+ddH2O For best results, use promptly after mixing.	5mg/mL

* Please note that Selleck tests the solubility of all compounds in-house, and the actual solubility may differ slightly from published values. This is normal and is due to slight batch-to-batch variations.

Chemical Information Download Celecoxib SDF

Molecular Weight	381.37
Formula	C₁₇H₁₄F₃N₃O₂S
CAS No.	169590-42-5
Storage	3 years -20°C powder
Storage	2 years -80°C in solvent
Synonyms	SC 58635
Smiles	CC1=CC=C(C=C1)C2=CC(=N[N]2C3=CC=C(C=C3)[S](N)(=O)=O)C(F)(F)F

In vivo Formulation Calculator (Clear solution)

Step 1: Enter information below (Recommended: An additional animal making an allowance for loss during the experiment)

Dosage

mg/kg

Average weight of animals

Dosing volume per animal

Number of animals

Step 2: Enter the in vivo formulation (Different batches have different solubility ratios, please contact Selleck to provide you with the correct ratio)

% DMSO+ % + % Tween 80+ % ddH₂O

Calculate Reset

Calculation results:

Working concentration： mg/ml；

Method for preparing DMSO master liquid: ： mg drug pre-dissolved in μL DMSO (Master liquid concentration mg/mL， Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug. )

Method for preparing in vivo formulation：Take DMSO master liquid, next addμL PEG300， mix and clarify, next addμL Tween 80，mix and clarify, next add μL ddH₂O，mix and clarify.

Note：1.Please make sure the liquid is clear before adding the next solvent.
2.Be sure to add the solvent(s) in order. You must ensure that the solution obtained, in the previous addition, is a clear solution before proceeding to add the next solvent. Physical methods such as vortex, ultrasound or hot water bath can be used to aid dissolving.

Bio Calculators

Molarity Calculator

Calculate the mass, volume or concentration required for a solution. The Selleck molarity calculator is based on the following equation:

Mass (mg) = Concentration (mM) × Volume (mL) × Molecular Weight (g/mol)

*When preparing stock solutions, please always use the batch-specific molecular weight of the product found on the via label and MSDS / COA (available on product pages).

Dilution Calculator

Calculate the dilution required to prepare a stock solution. The Selleck dilution calculator is based on the following equation:

Concentration _(start) x Volume _(start) = Concentration _(final) x Volume _(final)

This equation is commonly abbreviated as: C1V1 = C2V2 ( Input Output )

* When preparing stock solutions always use the batch-specific molecular weight of the product found on the vial label and MSDS / COA (available online).

The Serial Dilution Calculator Equation

Serial Dilutions
Concertration (start):
Dilution-folds:

Computed Result

C1=C0/X	C1:	LOG(C1):
C2=C1/X	C2:	LOG(C2):
C3=C2/X	C3:	LOG(C3):
C4=C3/X	C4:	LOG(C4):
C5=C4/X	C5:	LOG(C5):
C6=C5/X	C6:	LOG(C6):
C7=C6/X	C7:	LOG(C7):
C8=C7/X	C8:	LOG(C8):

Molecular Weight Calculator

Enter the chemical formula of a compound to calculate its molar mass and elemental composition:

Tip: Chemical formula is case sensitive. C10H16N2O2 c10h16n2o2

Instructions to calculate molar mass (molecular weight) of a chemical compound:

To calculate molar mass of a chemical compound, please enter its chemical formula and click 'Calculate'.

Definitions of molecular mass, molecular weight, molar mass and molar weight:

Molecular mass (molecular weight) is the mass of one molecule of a substance and is expressed in the unified atomic mass units (u). (1 u is equal to 1/12 the mass of one atom of carbon-12)
Molar mass (molar weight) is the mass of one mole of a substance and is expressed in g/mol.

Molarity Calculator

Clinical Trial Information (data from https://clinicaltrials.gov, updated on 2020-05-15)

NCT Number	Recruitment	interventions	Conditions	Sponsor/Collaborators	Start Date	Phases
NCT03896113	Recruiting	Drug: Celecoxib 200mg capsule	Endometrium Cancer	Cliniques universitaires Saint-Luc- Université Catholique de Louvain	November 13 2019	Phase 2
NCT03643744	Recruiting	Drug: Celecoxib 200mg\|Drug: Placebo	Actinic Keratosis\|Photodynamic Therapy	Jeffrey B. Travers MD PhD\|Wright State Physicians	April 1 2019	Phase 1
NCT01344200	Not yet recruiting	Drug: Celecoxib	Pharmacokinetics of Celecoxib in Children	Children''s Hospital of Eastern Ontario	March 2019	Phase 4
NCT02876094	Recruiting	Drug: celecoxib	Spinal Muscular Atrophy (SMA)	Hugh McMillan\|Families of Spinal Muscular Atrophy\|Gwendolyn Strong Foundation\|Children''s Hospital of Eastern Ontario	January 29 2019	Phase 2
NCT03672162	Recruiting	Procedure: Total abdominal hysterectomy	Total Abdominal Hysterectomy Pain Acute PostoperativeGabapentin Celecoxib	Rajavithi Hospital	September 1 2018	Not Applicable

Tech Support

Answers to questions you may have can be found in the inhibitor handling instructions. Topics include how to prepare stock solutions, how to store inhibitors, and issues that need special attention for cell-based assays and animal experiments.

Handling Instructions

Tel: +1-832-582-8158 Ext:3

If you have any other enquiries, please leave a message.

Frequently Asked Questions

Question 1:
I am doing an animal experiment with mice and planning to administrate S1261 via oral gavage. what are your recommendations for diluting the compound?
Answer:
For oral administration, Celecoxib can be dissolved in vehicle one: "0.5% methyl cellulose and 0.025% Tween-20", or the vehicle 2 "2% DMSO/30% PEG 300/5% Tween 80/ ddH2O".

COX Signaling Pathway Map

COX Inhibitors with Unique Features

Pan COX inhibitor

Naproxen : Pan-COX inhibitor, COX-1, IC50=8.7 μM; COX-2, IC50=5.2 μM.
Most Potent COX Inhibitor

Lornoxicam : COX-1, IC50=5 nM; COX-2, IC50=8 nM.
FDA-approved COX Inhibitor

Ibuprofen : Approved by FDA for relieving pain, alleviating fever,and reducing inflammation.
Classic COX Inhibitor

Ketorolac : Non-selective COX inhibitor of COX-1 and COX-2 with IC50 of 1.23 μM and 3.50 μM, respectively.

Related COX Products

Xanthohumol ^New

Xanthohumol, a prenylated chalcone from hop, inhibits COX-1 and COX-2 activity and shows chemopreventive effects. Phase 1.
AZD3839 ^New

AZD3839 is a potent and selective BACE1 inhibitor with K_i of 26.1 nM, about 14-fold selectivity over BACE2. Phase 1.
A-438079 HCl ^New

A-438079 HCl is a potent, and selective P2X7 receptor antagonist with pIC50 of 6.9.
Indomethacin

Indomethacin is a nonselective COX1 and COX2 inhibitor with IC50 of 0.1 μg/mL and 5 μg/mL, respectively, used to reduce fever, pain, stiffness, and swelling.
Lornoxicam

Lornoxicam is a non-steroidal COX-1/COX-2 inhibitor, used as an anti-inflammatory drug to treat pain, osteoarthritis, and rheumatoid arthritis.
Aspirin

Aspirin is a salicylate, and irreversible COX1 and COX2 inhibitor, used as an analgesic to relieve minor aches and pains, as an antipyretic to reduce fever, and as an anti-inflammatory medication.
Rofecoxib

Rofecoxib is a COX-2 inhibitor with IC50 of 18 nM.
Ketorolac

Ketorolac is a non-selective COX inhibitor of COX-1 and COX-2 with IC50 of 1.23 μM and 3.50 μM, respectively.

Features:A COX-1 preferential inhibitor among currently marked nonsteroidal anti-inflammatory drugs (NSAIDs).
Bufexamac

Bufexamac is a COX inhibitor for IFN-α release with EC50 of 8.9 μM.

Features:A specific inhibitor of class IIB histone deacetylases.
Ibuprofen

Ibuprofen (Dolgesic) is an anti-inflammatory inhibitor targeting COX-1 and COX-2 with IC50 of 13 μM and 370 μM, respectively.

Features:Considered a core medicine in the WHO's "WHO Model List of Essential Medicines" (a list of the minimum medical requirements for a basic healthcare system).

Choose Your Country or Region

By Signaling Pathways

By product type

Celecoxib